HHIPL1: A Potential Drug Target Or Biomarker (G84439)

Target Name: HHIPL1

NCBI ID: G84439

HHIPL1

HHIPL1: A Potential Drug Target Or Biomarker

HHIPL1 (UNQ9245) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its primary function is to regulate the levels of phosphorus in these tissues, which are essential for various biological processes. HHIPL1 has been identified as a potential drug target or biomarker due to its unique structure and the diseases it is associated with.

HHIPL1 is a member of the HIPL family, which includes several related proteins that are involved in the regulation of phosphorus homeostasis. The HIPL family is characterized by the presence of a unique N-terminal domain that is involved in the formation of a covalent complex with phosphate species. This domain is known as the HIPL domain and is a common feature of many proteins that are involved in phosphorus homeostasis.

HHIPL1 is expressed in a variety of tissues and is involved in the regulation of phosphorus levels in these tissues. For example, it is expressed in the brain, where it is thought to play a role in the regulation of neurotransmitter synthesis and release. HHIPL1 is also expressed in the heart, where it is involved in the regulation of contractility and heart rate. Additionally, it is expressed in the kidneys, where it is involved in the regulation of water and electrolyte balance.

HHIPL1 is also associated with several diseases, including diabetes, hypertension, and chronic kidney disease. These diseases are characterized by the presence of high levels of phosphorus in the body, which can lead to a range of negative health consequences. For example, high levels of phosphorus in the blood can cause muscle weakness, nerve damage, and heart arrhythmias. In addition, high levels of phosphorus in the kidneys can cause kidney damage and reduce kidney function.

Because of its association with these diseases and its unique structure, HHIPL1 has been identified as a potential drug target or biomarker. Researchers are currently working to develop compounds that can interact with the HHIPL1 protein and treat diseases associated with high levels of phosphorus in the body. For example, researchers have developed a compound called PF-5672 that is designed to interact with HHIPL1 and inhibit its activity. Studies have shown that this compound is able to lower phosphorus levels in test subjects with elevated phosphorus levels, indicating that it has the potential to be a useful treatment for diseases associated with high levels of phosphorus.

In addition to its potential as a drug target or biomarker, HHIPL1 is also a promising candidate for use as a diagnostic tool. The HHIPL1 protein is expressed in a variety of tissues and is involved in the regulation of phosphorus homeostasis. This makes it an attractive candidate for use as a diagnostic tool in a variety of diseases. For example, HHIPL1 levels may be elevated in individuals with diabetes, as a result of the increased demand for insulin in the body. Similarly, HHIPL1 levels may be elevated in individuals with hypertension, as a result of the increased demand for blood vessels to pump blood to the body's tissues.

In conclusion, HHIPL1 is a protein that is expressed in various tissues of the body and is involved in the regulation of phosphorus homeostasis. Its unique structure and association with diseases make it a promising candidate for use as a drug target or biomarker. Additionally, HHIPL1 is also a promising candidate for use as a diagnostic tool in a variety of diseases. Further research is needed to fully understand the role of HHIPL1 in the regulation of phosphorus homeostasis and its potential as a drug target or biomarker.

Protein Name: HHIP Like 1

The "HHIPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HHIPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets